 |
|
 |
 |

Home > Company Index > Drugs > Biotechnology-Medicine > Telik, Inc.
 |
Telik, Inc. |
 |
 |
 |
NEWS FROM THE WIRES |
 |
Telik Inc files for 4 million share offering Aug 17 2001 05:25 PM PDT
> More WIRE STORIES about this company
PROFILE |
 |
Go Telik on the mountain: Telik discovers new drugs, focusing mainly on new treatments for cancer, diabetes, inflammatory diseases, and stroke. The company uses its proprietary Target-Related Affinity Profiling (TRAP) technology to identify potential drug compounds by analyzing the way they interact with proteins. Lead drug candidate TLK286 targets chemotherapy-resistant tumors, while TLK199 stimulates bone marrow to fight blood disorders. Telik has research and development agreements with such companies as Sanwa Kagaku Kenkyusho (a unit of Japanese drugmaker Suzuken), Sankyo, COR Therapeutics, and Scios. Sanwa, which holds Asian marketing rights to some of Telik's drug candidates, owns about 10% of the firm.
COMPETITION |
 |
Amgen Inc. (AMGN)
Novo Nordisk A/S (NVO)
Regeneron Pharmaceuticals, Inc. (REGN)
|
 |
STOCK ANALYSIS |
 |
FURTHER ANALYSIS
Advanced Charting
Deals
FINANCIAL OVERVIEW |
 |
Fiscal Year-End: December
2000 Sales (mil.): 2.80
1-Yr. Sales Growth: (33.3)%
Employees: 43
Revenue per employee: $65,116.28
KEY PEOPLE |
 |
Michael M. Wick
CEO
Cynthia M. Butitta
CFO
CONTACT INFO |
 |
750 Gateway Blvd.
South San Francisco, CA 94080
US
Phone: 650-244-9303
Fax: 650-244-9388
Online: Web Site
|
 |
 |
 |
|
Hoover's Company Capsule
Copyright © 2001, Hoover's Inc. Austin, Texas.
For changes and updates, contact Hoover's directly.
|

|
 |
 |
|
 |